Inhibition of FNDC1 suppresses gastric cancer progression by interfering with Gβγ-VEGFR2 complex formation

Gastric cancer (GC) is a prevalent digestive tract malignant tumor characterized by an insidious onset, ease of metastasis, rapid growth, and poor prognosis. Here, we report that fibronectin type III domain containing 1 (FNDC1) has high expression in GC and indicates poor outcomes in patients with GC. FNDC1 over-expression or knockdown promotes or inhibits tumorigenesis and metastasis, respectively. The expression of FNDC1 is upregulated by TWIST1, strengthening its interaction with Gβγ and VEGFR2. The formation of the trimers, TWIST1 plus Gβγ and VEGFR2, increases VEGFR2 phosphorylation and Gβγ trafficking, which activates RAS-MAPK and PI3K-AKT signaling, benefiting GC progression. In this study, we demonstrated that arsenite can efficiently suppress FNDC1 expression, attenuating the formation of the trimers and downstream pathways. Altogether, our results indicate that FNDC1 might be a promising target for clinical treatment and prognostic judgment, while FNDC1 inhibition by arsenite provides a new opportunity for overcoming this fatal disease. [Display omitted] •FNDC1-mediated proliferation and metastasis of gastric cancer is overcome by arsenite•FNDC1 is highly expressed and upregulated by TWIST1 in human gastric cancer (GC) cells•FNDC1-VEGFR2-Gβγ complex enhances proliferation and metastasis of GC cells•Arsenite suppresses proliferation and metastasis of GC cells by targeting FNDC1•FNDC1 may act as a potential prognostic and therapeutic target for GC Drugs; Molecular biology; Cancer